financetom
Business
financetom
/
Business
/
What's Going On With Marvell Technology (MRVL) Stock?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Marvell Technology (MRVL) Stock?
Feb 27, 2025 11:47 AM

Marvell Technology Inc ( MRVL ) shares are trading lower by 4.27% to $90.85 during Thursday's session, reversing lower following earlier strength, following Nvidia's strong earnings report.

What To Know: While Nvidia's record-breaking fourth-quarter results underscored surging demand for AI infrastructure, they also reinforced its dominance in AI computing, causing investors to reassess expectations for other semiconductor firms like Marvell ( MRVL ).

Read Also: Pending Home Sales Crash To Record Low, Jobless Claims Soar: Wall Street Reacts

Marvell ( MRVL ) plays a crucial role in AI infrastructure by providing high-speed networking, custom silicon and data processing solutions for hyperscalers and enterprises.

The company has been expanding its presence in AI through acquisitions and partnerships, including its investment in custom ASICs, which serve as an alternative to Nvidia's GPUs for certain AI workloads. Its acquisition of Innovium also bolstered its high-speed Ethernet switching capabilities, critical for AI-driven data centers.

What Else: Despite Nvidia's continued market leadership, Marvell ( MRVL ) could remain positioned to benefit from the expanding AI ecosystem. The rapid growth of AI workloads requires advanced networking and compute solutions, areas where Marvell ( MRVL ) has a strong presence.

Read Also: Trump’s Tariffs, Potential ‘Stagflation’: What’s Driving Markets Thursday?

Investors can gain exposure to MRVL by investing in the VanEck Semiconductor ETF ( SMH ) .

How To Buy MRVL Stock

By now you're likely curious about how to participate in the market for Marvell Technology ( MRVL ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

In the case of Marvell Technology ( MRVL ), which is trading at $92.38 as of publishing time, $100 would buy you 1.08 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

According to data from Benzinga Pro, MRVL has a 52-week high of $127.48 and a 52-week low of $53.19.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Smith Douglas Q3 home closing revenue falls 6%, net orders rise 15%
Smith Douglas Q3 home closing revenue falls 6%, net orders rise 15%
Nov 5, 2025
Overview * Smith Douglas Q3 home closing revenue falls 6% yr/yr, with gross margin declining to 21% * Net new home orders rise 15% in Q3, showing growth in demand * Active community count up 32% to 98, reflecting expansion efforts Outlook * Company did not provide specific financial guidance for future quarters Result Drivers * EXPANSION EFFORTS - Co...
Biotech firm Arvinas' Q3 net loss narrows
Biotech firm Arvinas' Q3 net loss narrows
Nov 5, 2025
Overview * Arvinas ( ARVN ) Q3 revenue drops significantly year-over-year, impacted by completed Novartis agreements * Net loss for Q3 narrows compared to last year * R&D expenses decrease due to lower external and personnel costs Outlook * Arvinas ( ARVN ) plans to initiate a Phase 1b trial for ARV-102 in PSP patients in 1H 2026 * Company...
Bio-Techne misses quarterly sales estimates on weak biotech demand
Bio-Techne misses quarterly sales estimates on weak biotech demand
Nov 5, 2025
Nov 5 (Reuters) - Biotech firm Bio-Techne ( TECH ) missed its first-quarter revenue estimates on Wednesday, hurt by sluggish demand for its products amid soft biotech funding environment in China. Shares of the Minneapolis, Minnesota-based company, which develops products used in medical research, drug development and diagnostics, were down nearly 10% premarket following the results. During the quarter, we...
SolarEdge Q3 revenue beats estimates, loss narrows
SolarEdge Q3 revenue beats estimates, loss narrows
Nov 5, 2025
Overview * SolarEdge ( SEDG ) Q3 revenue grows 18% qtr/qtr, beating analyst expectations * Adjusted loss per share beats analyst estimates, reflecting improved financial performance * Company reports reduced net loss and operating expenses qtr/qtr Outlook * Company expects Q4 2025 revenue between $310 mln and $340 mln * Non-GAAP gross margin for Q4 2025 expected between 19% and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved